SNMMI 2026: Theranostics Pipelines and Novel PET Tracers Take Center Stage

At SNMMI 2026 in Los Angeles, theranostics dominated scientific sessions with new agent data, while non-FDG PET radiotracers signal a broadening diagnostic landscape. Specific efficacy or trial numbers not reported in source.

• Trade-press conference coverage: no peer-reviewed data or trial-level numbers were provided in the source snippet; findings should be treated as preliminary meeting highlights.
• Both therapeutic (theranostics pipeline agents) and diagnostic (novel PET radiotracers beyond FDG) tracks featured prominently, suggesting continued field expansion.
• Limitation: source is a trade-publication summary of meeting news, not a primary research report — claims lack quantitative detail and independent verification.

RadPigeon summaries are original and for information only. They are not clinical advice.